The nosology of tardive syndromes

Journal of the Neurological Sciences

Volumn 389, Issue , 2018, Pages 10-16

  Frei, Karen ^a   Truong, Daniel D ^b,c   Fahn, Stanley ^d   Jankovic, Joseph ^e   Hauser, Robert A ^f  

^a LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^b The Truong Neurosciences Institute   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEUROLOGICAL INSTITUTE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Extrapyramidal syndrome; Tardive akathisia; Tardive dyskinesia; Tardive dystonia; Tardive pain; Tardive parkinsonism; Tardive syndrome; Tardive tourettism; Tardive tremors

Indexed keywords

DOPAMINE 1 RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT;

AKATHISIA; ARTICLE; DISEASE CLASSIFICATION; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; HUMAN; MYOCLONUS; PAIN; PARKINSONISM; PRIORITY JOURNAL; TARDIVE DYSKINESIA; TIC; TREMOR; CLASSIFICATION; NOMENCLATURE;

AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; HUMANS; TARDIVE DYSKINESIA; TERMINOLOGY AS TOPIC;

EID: 85041740652     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2018.02.008     Document Type: Article

References (76)

1. Correll, C.U., Kane, J.M., Citrome, L.L., Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment. J. Clin. Psychiatry 78:8 (2017), 1136–1147.
2. Faurbye, A., Rasch, P.J., Petersen, P.B., Brandborg, G., Pakkenberg, H., Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr. Scand. 40 (1964), 10–27.
3. Vijayakumar, D., Jankovic, J., Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia. Drugs 76:7 (2016), 779–787.
4. Waln, O., Jankovic, J., An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y), 3, 2013.
5. Savitt, D., Jankovic, J., Tardive syndrome. J. Neurol. Sci., 2018, 10.1016/j.jns.2018.02.005 [in this issue].
6. Faurbye, A., Uhrbrand, L., Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy. Psychopharmacologia 1:5 (1960), 408–418.
7. Wilson, S.A.K., Progressive lenticular degeneration: a familial nervous system disease associated with cirrhosis of the liver. Brain 34 (1912), 295–509.
8. Fahn, S., Classification of movement disorders. Mov. Disord. 26:6 (2011), 947–957.
9. Obeso, J.A., The movement disorders journal 2016 and onward. Mov. Disord. 31:1 (2016), 1–2.
10. Steck, H., Extrapyramidal and diencephalic syndrome in the course of largactil and serpasil treatments. Ann. Med. Psychol. (Paris) 112:2 5 (1954), 737–744.
11. Delay, J., Deniker, P., Chlorpromazine and neuroleptic treatments in psychiatry. J. Clin. Exp. Psychopathol. 17:1 (1956), 19–24.
12. Deniker, P., Psychophysiologic aspects of the new chemotherapeutic drugs in psychiatry; some practical features of neuroleptics in order to screen new drugs. J. Nerv. Ment. Dis. 124:4 (1956), 371–376.
13. Delay, J., Deniker, P., Drug-induced extrapyramidal syndromes. Vinken, P.J., Bruyn, G., (eds.) Handbook of Clinical Neurology Diseases of the Basal Ganglia, Vol 6, 1968, North Holland Publishing, Amsterdam, 246–266.
14. Hall, R.A., Jackson, R.B., Swain, J.M., Neurotoxic reactions resulting from chlorpromazine administration. J. Am. Med. Assoc. 161:3 (1956), 214–218.
15. Cohen, I.M., Complications of chlorpromazine therapy. Am. J. Psychiatry 113:2 (1956), 115–121.
16. Hollister, L.E., Complications from the use of tranquilizing drugs. N. Engl. J. Med. 257:4 (1957), 170–177.
17. Kulenkampff, C., Tarnow, G., Ein eigentümliches Syndrom in oralen Bereich bei Megaphenappikation. [An unusual syndrome in the oral region caused by administration of megaphen]. Nervenarzt 27:4 (1956), 178–180.
18. Shanon, J., Kaplan, S.M., Pierce, C.M., Ross, W.D., An interesting reaction to a tranquilizer: tonic seizures with perphenazine (trilafon). Am. J. Psychiatry, 114(6), 1957, 556.
19. Schônecker, M., Ein eigentumliches Syndrom im oralen Bereich bei Megaphen Applikation, [An unusual syndrome in the oral region caused by administration of megaphen]. Nervenarzt, 28, 1957, 35.
20. Crane, G.E., Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature. Am. J. Psychiatry 124:8 (1968), 40–47.
21. Schônecker, M., Paroxysmale Dyskinesen als Megaphenwirkung [Paroxysmal dyskinesia as the effect of megaphen]. Nervenarzt 28:12 (1957), 550–553.
22. Ayd, F.J. Jr., Clinical indications and toxicity of prolonged perphenazine therapy. N. Engl. J. Med. 261:4 (1959), 172–174.
23. Hollister, L.E., Complications from psychotherapeutic drugs. N. Engl. J. Med. 264 (1961), 291–293.
24. Sigwald, J., Bouttier, D., Raymondeaud, C., Piot, C., Quatre cas de dyskinesie facio-bucco-linguo-masticatrice a l'evolution prolongee secondaire a un traitement par les neuroleptiques. [4 cases of facio-bucco-linguo-masticatory dyskinesis of prolonged development following treatment with neuroleptics]. Rev. Neurol. (Paris) 100 (1959), 751–755.
25. Paulson, G.W., Historical comments on tardive dyskinesia: a neurologist's perspective. J. Clin. Psychiatry 66:2 (2005), 260–264.
26. Brandrup, E., Tetrabenacine treatment in persisting dyskinesia caused by psychopharmaca. Am. J. Psychiatry 118 (1961), 551–552.
27. Druckman, R., Seelinger, D., Thulin, B., Chronic involuntary movements induced by phenothiazines. J. Nerv. Ment. Dis. 135 (1962), 69–76.
28. Hunter, R., Earl, C.J., Thronicroft, S., An apparently irreversible syndrome of abnormal movements following phenothiazine medication. Proc. R. Soc. Med. 57 (1964), 758–762.
29. Hunter, R., Earl, C.J., Janz, D., A syndrome of abnormal movements and dementia in leucotomized patients treated with phenothiazines. J. Neurol. Neurosurg. Psychiatry 27 (1964), 219–223.
30. Evans, J.H., Persistent oral dyskinesia in treatment with phenothiazine derivatives. Lancet 1:7383 (1965), 458–460.
31. Keegan, D.L., Rajput, A.H., Drug induced dystonia tarda: treatment with L-dopa. Dis. Nerv. Syst. 34:3 (1973), 167–169.
32. Burke, R.E., Fahn, S., Jankovic, J., Marsden, C.D., Lang, A.E., Gollomp, S., Ilson, J., Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 32:12 (1982), 1335–1346.
33. Fahn, S., Tardive dyskinesia may be only akathisia. N. Engl. J. Med. 299:4 (1978), 202–203.
34. Fahn, S., Treatment of tardive dyskinesia: use of dopamine-depleting agents. Clin. Neuropharmacol. 6:2 (1983), 151–158.
35. Burke, R.E., Kang, U.J., Jankovic, J., Miller, L.G., Fahn, S., Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov. Disord. 4:2 (1989), 157–175.
36. Fahn, S., Jankovic, J., Hallett, M., Principles and Practice of Movement Disorders. 2nd ed., 2011, Saunders Elsevier, Edinburgh, 430–431.
37. Jankovic, J., Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert. Opin. Pharmacother. 17:18 (2016), 2461–2470.
38. Reches, A., Burke, R.E., Kuhn, C.M., Hassan, M.N., Jackson, V.R., Fahn, S., Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J. Pharmacol. Exp. Ther. 225:3 (1983), 515–521.
39. Burke, R.E., Reches, A., Traub, M.M., Ilson, J., Swash, M., Fahn, S., Tetrabenazine induces acute dystonic reactions. Ann. Neurol. 17:2 (1985), 200–202.
40. Burke, R.E., Fahn, S., Mayeux, R., Weinberg, H., Louis, K., Willner, J.H., Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology 31:8 (1981), 1022–1025.
41. Johnson, G.F., Hunt, G.E., Rey, J.M., Incidence and severity of tardive dyskinesia increase with age. Arch. Gen. Psychiatry, 39(4), 1982, 486.
42. Gardos, G., Cole, J.O., Haskell, D., Marby, D., Paine, S.S., Moore, P., The natural history of tardive dyskinesia. J. Clin. Psychopharmacol. 8:4 Suppl (1988), 31S–37S.
43. Schooler, N.R., Kane, J.M., Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry 39:4 (1982), 486–487.
44. Vijayakumar, D., Jankovic, J., Drug-induced dyskinesia, part 1: treatment of levodopa-induced dyskinesia. Drugs 76:7 (2016), 759–777.
45. Kang, U.J., Burke, R.E., Fahn, S., Natural history and treatment of tardive dystonia. Mov. Disord. 1:3 (1986), 193–208.
46. Kiriakakis, V., Bhatia, K.P., Quinn, N.P., Marsden, C.D., The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain 121:Pt 11 (1998), 2053–2066.
47. Barnes, T.R., Braude, W.M., Persistent akathisia associated with early tardive dyskinesia. Postgrad. Med. J. 60:703 (1984), 359–361.
48. Sachdev, P., The classification of akathisia. Mov. Disord. 10:2 (1995), 235–237.
49. Weiner, W.J., Luby, E.D., Persistent akathisia following neuroleptic withdrawal. Ann. Neurol. 13:4 (1983), 466–467.
50. Klawans, H.L., Falk, D.K., Nausieda, P.A., Weiner, W.J., Gilles de la Tourette syndrome after long-term chlorpromazine therapy. Neurology 28:10 (1978), 1064–1066.
51. Bharucha, K.J., Sethi, K.D., Tardive tourettism after exposure to neuroleptic therapy. Mov. Disord. 10:6 (1995), 791–793.
52. Fountoulakis, K.N., Samara, M., Siapera, M., Iacovides, A., Tardive Tourette-like syndrome: a systematic review. Int. Clin. Psychopharmacol. 26:5 (2011), 237–242.
53. Jankovic, J., Jimenez-Shahed, J., Budman, C., Coffey, B., Murphy, T., Shprecher, D., Stamler, D., Deutetrabenazine in tics associated with tourette syndrome. Tremor Other Hyperkinet Mov (N Y), 6, 2016, 422.
54. Stacy, M., Jankovic, J., Tardive tremor. Mov. Disord. 7:1 (1992), 53–57.
55. Storey, E., Lloyd, J., Tardive tremor. Mov. Disord. 12:5 (1997), 808–810.
56. Delecluse, F., Elosegi, J.A., Gerard, J.M., A case of tardive tremor successfully treated with clozapine. Mov. Disord. 13:5 (1998), 846–847.
57. Shprecher, D., Sensory trick with metoclopramide-associated tardive tremor. BMJ Case Rep., 2012, 10.1136/bcr-11-2011-5156.
58. Kertesz, D.P., Swartz, M.V., Tadger, S., Plopski, I., Barak, Y., Tetrabenazine for tardive tremor in elderly adults: a prospective follow-up study. Clin. Neuropharmacol. 38:1 (2015), 23–25.
59. Tominaga, H., Fukuzako, H., Izumi, K., Koja, T., Fukuda, T., Fujii, H., Matsumoto, K., Sonoda, H., Imamura, K., Tardive myoclonus. Lancet, 1(8528), 1987, 322.
60. Little, J.T., Jankovic, J., Tardive myoclonus. Mov. Disord. 2:4 (1987), 307–311.
61. Hierholzer, R.W., Tardive dyskinesia with complaints of pain. Am. J. Psychiatry, 146(6), 1989, 802.
62. Ford, B., Greene, P., Fahn, S., Oral and genital tardive pain syndromes. Neurology 44:11 (1994), 2115–2119.
63. Montagna, P., Pierangeli, G., Avoni, P., Cortelli, P., Tinuper, P., Lugaresi, E., Tardive pain. Neurology 45:11 (1995), 2113–2114.
64. Tschopp, L., Salazar, Z., Micheli, F., Botulinum toxin in painful tardive dyskinesia. Clin. Neuropharmacol. 32:3 (2009), 165–166.
65. Fahn, S., Jankovic, J., Hallett, M., Principles and Practice of Movement Disorders. 2nd ed., 2011, Elsevier/Saunders, Edinburgh; New York, 427–440.
66. Farde, L., Nordstrom, A.L., Wiesel, F.A., Pauli, S., Halldin, C., Sedvall, G., Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 49:7 (1992), 538–544.
67. Morley, J.F., Pawlowski, S.M., Kesari, A., Maina, I., Pantelyat, A., Duda, J.E., Motor and non-motor features of Parkinson's disease that predict persistent drug-induced Parkinsonism. Parkinsonism Relat. Disord. 20:7 (2014), 738–742.
68. Bocola, V., Fabbrini, G., Sollecito, A., Paladini, C., Martucci, N., Neuroleptic induced parkinsonism: MRI findings in relation to clinical course after withdrawal of neuroleptic drugs. J. Neurol. Neurosurg. Psychiatry 60:2 (1996), 213–216.
69. Olivares Romero, J., Arjona Padillo, A., Diagnostic accuracy of 123 I-FP-CIT SPECT in diagnosing drug-induced parkinsonism: a prospective study. Neurologia 28:5 (2013), 276–282.
70. Lorberboym, M., Treves, T.A., Melamed, E., Lampl, Y., Hellmann, M., Djaldetti, R., [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov. Disord. 21:4 (2006), 510–514.
71. Rajput, A.H., Rozdilsky, B., Hornykiewicz, O., Shannak, K., Lee, T., Seeman, P., Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Arch. Neurol. 39:10 (1982), 644–646.
72. Bower, J.H., Dickson, D.W., Taylor, L., Maraganore, D.M., Rocca, W.A., Clinical correlates of the pathology underlying parkinsonism: a population perspective. Mov. Disord. 17:5 (2002), 910–916.
73. Shuaib, U.A., Rajput, A.H., Robinson, C.A., Rajput, A., Neuroleptic-induced parkinsonism: clinicopathological study. Mov. Disord. 31:3 (2016), 360–365.
74. Muller, T., Valbenazine for the treatment of tardive dyskinesia. Expert. Rev. Neurother. 17:12 (2017), 1135–1144.
75. Anderson, K.E., Stamler, D., Davis, M.D., Factor, S.A., Hauser, R.A., Isojarvi, J., Jarskog, L.F., Jimenez-Shahed, J., Kumar, R., McEvoy, J.P., Ochudlo, S., Ondo, W.G., Fernandez, H.H., Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry 4:8 (2017), 595–604.
76. Fernandez, H.H., Factor, S.A., Hauser, R.A., Jimenez-Shahed, J., Ondo, W.G., Jarskog, L.F. et al., Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology 88:21 (2017), 2003–2010.